AstraZeneca sets ambition to deliver $80 billion Total Revenue by …
WEBMay 21, 2024 · Today AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023. This will be achieved through significant growth in its existing oncology, biopharmaceuticals and rare disease portfolio, and by launching an expected 20 new medicines before the end of the decade.
Media Centre - AstraZeneca
WEBSep 16, 2024 · Medical releases. AstraZeneca Media centre. The Hub for our Articles, Press Releases and Webcasts & Presentations.
AstraZeneca - Research-Based BioPharmaceutical Company
WEBKeep up to date with the latest news. At AstraZeneca, we’re committed to diving deep into the root cause of heart failure to determine the changes we need to make in ways we treat this disease, transform care and ultimately improve outcomes.
9M and Q3 2023 results - AstraZeneca
WEB9M and Q3 2023 results. PUBLISHED 9 November 2023. Pascal Soriot, Chief Executive Officer, AstraZeneca, commenting on the results said: “Our company continued its strong growth trajectory in the third quarter with Total Revenue from our non‑COVID-19 medicines up 13% compared to last year.
AstraZeneca to acquire Fusion to accelerate the development of …
WEBMar 19, 2024 · AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing ...
AstraZeneca to acquire Icosavax, including potential first-in-class …
WEBDec 12, 2023 · The proposed acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus (RSV), strengthening AstraZeneca’s Vaccines & Immune Therapies late-stage pipeline with Icosavax’s lead investigational vaccine candidate, IVX-A12.
Beyfortus approved in the US for the prevention of RSV
WEBJul 17, 2023 · AstraZeneca and Sanofi’s Beyfortus (nirsevimab) has been approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their ...
Coronavirus (COVID-19) information & research hub - AstraZeneca
WEBFrom the latest news on antibody testing to our ever-developing covid research, learn about our efforts to combat COVID-19.
Q1 2024 results - AstraZeneca
WEBApr 25, 2024 · “AstraZeneca had a very strong start in 2024 with substantial Total Revenue growth of 19% in the first quarter. Our strong pipeline momentum continued and already this year we announced positive trial results for Imfinzi and Tagrisso that were unprecedented in lung cancer, the data from both of these studies will be presented during the ASCO ...
AZD1222 vaccine met primary efficacy endpoint in ... - AstraZeneca
WEBNov 23, 2020 · Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19, the primary endpoint, and no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine. There were a …
- Some results have been removed
Skip to content